The partnership intends to use in vivo electrophysiology solutions to drive neuroscience research and accelerate neurological drug discovery and commercialisation
The collaboration focuses on expediting neuroscience drug discovery. (Credit: Stefano Bucciarelli on Unsplash)
ACROBiosystems, a US-based biotech company through ACRO Certify and under its Aneuro brand, has launched in vivo electrophysiology solutions for research on neuroscience in partnership with Diagnostic Biochips.
The partnership intends to accelerate neurological drug discovery and commercialisation.
Diagnostic Biochips is an American biosensor platform technology firm. It has developed a proprietary sensor functionalisation process and a range of biosensors to help the medical monitoring process.
ACROBiosystems said that the available probes for in vivo electrophysiology are made to function without a headstage. This reduces the physical strain on the animal heads without making up for it with signal channels.
Additionally, deep-array electrodes with a 90mm recording depth over 128 channels are also offered.
Apart from the probes, artificial intelligence (AI) and cloud-based data analysis software are also available to drive the structural and functional analysis of brain circuits, the identification of electrophysiological biomarkers, and drug screening.
The biotechnology company said that beginner’s manuals and training are available to help people get their experiments running if they want to make their first step into the neurosciences.
Aneuro includes all in vivo electrophysiology and other neurological drug development products such as pre-formed fibrils (PFFs) and Tau.
It also includes several other protein antigens related to neurological diseases like Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, and brain tumours.
Acro Certify, which is ACROBiosystems’ new business model, is designed to assist partners to enter global markets and establish a global brand footprint.
This covers marketing and sales channels, quality assurance, product and brand value, and global logistics. All of these are aimed at giving pharmaceutical producers all around the world access to advanced technologies, said ACROBiosystems.